A Sham Controlled Study of the Effects of Ultrasonic Shockwaves as a Treatment for Chronic Pelvic Pain
- Conditions
- Chronic Pelvic Pain
- Interventions
- Device: Low intensity extracorporeal shockwave therapyDevice: Sham low intensity extracorporeal shockwave therapy
- Registration Number
- NCT02042651
- Lead Sponsor
- Herlev Hospital
- Brief Summary
Introduction:
Chronic pelvic pain with unknown pathology is a condition that affects both men and women. the condition is defined as pelvic pain lasting for a minimum of 6 months without any known etiology eg. cancer, infection or inherent anatomical abnormalities. Low intensity extracorporeal shockwave therapy (LIESWT) enables the practitioner to deliver a small amount of energy approximately 5 cm under the skin of the patient without damaging the skin. This have been shown to increase blood flow and accelerate healing which could also be beneficial in chronic pelvic pain patients.The purpose of this study is to investigate the effects of LIESWT on chronic pelvic pain.
Methods:
All patients will be treated at the Birthe Bonde clinic, in Copenhagen, Denmark.
The investigators anticipate to include 100 chronic pelvic pain patients in the study.
included patients will be randomized into two groups: active treatment or sham treatment.
All patients will be required to provide a urine sample and a semen sample prior to final inclusion. Samples will be analyzed for microbial growth. Furthermore, patients will undergo a digital rectal exploration and finally all patients is required to provide an informed consent in order to be included in the study.
A Storz Doulith SD1 T-Top (CE1275) will be used to generate shockwaves. Patients will receive the treatment once a week until their symptoms have seized or for a maximum of 6 times. Each treatment consists of 3000 shockwaves applied to the perineum with a energy density of 0.25-0.40 millijoule(mJ)/mm2 and a frequency of 3 hz.
Participants will fill out a questionnaire one week before the treatment, one week, four weeks, and twelve weeks after the last treatment.
Possible gains from this study:
The investigators hope to provide further evidence for this treatment and consequently be able to offer the treatment as an alternative to the very limited array of treatments existing for this group of patients today.
Ethics, funding, and publication:
The study is performed in compliance with the Helsinki declaration. External funding have been applied for but not yet received. Participants will be informed of sources of external funding. The result of the study will be published as soon as possible, preferably in a peer-reviewed international journal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Male
- Target Recruitment
- Not specified
- pelvic pain with a duration of more than 6 months
- be able to read and understand the study information
- known etiology for pelvic pain eg. cancer, infection, inherent abnormalities.
- diagnosed with hemophilia
- receiving anti thrombotic therapy other than hearth magnyl
- diagnosed with thrombocytosis
- active cancer
- treated with IV glucocorticoids within the last 6 months
- disease in the rectal area
- abnormal digital rectal exploration
- bacteriospermia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Low intensity extracorporeal shockwave therapy Low intensity extracorporeal shockwave therapy Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum. Sham low intensity extracorporeal shockwave therapy Sham low intensity extracorporeal shockwave therapy Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
- Primary Outcome Measures
Name Time Method Change in NIH-Chronic Prostatitis Symptom Index Change from baseline to twelve weeks after final treatment A questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain, urinary symptoms, and quality of life.
- Secondary Outcome Measures
Name Time Method Change in The International Index of Erectile Function 5 Change from baseline to twelve weeks after final treatment Questionnaire designed to evaluate erectile capabilities. The questionnaire provides a score between 5 and 25.
Change in The International prostate symptom score Change from baseline to twelve weeks after final treatment A questionnaire designed to provide information on lower urinary tract symptoms and their impact on quality of life. scores range from 0 to 35.
Global satisfaction score Twelve weeks after final treatment One question designed to estimate treatment satisfaction on a four point Likert scale.
Trial Locations
- Locations (1)
Birthe bonde klinikken
🇩🇰Copenhagen E, Copenhagen, Denmark